KalVista Pharmaceuticals Inc
WKN: A2DG49 / ISIN: US4834971032Carbylan Therapeutics
| eröffnet am: | 22.08.16 08:59 von: | WiFi4 |
| neuester Beitrag: | 24.04.21 22:56 von: | Sabrinaidsma |
| Anzahl Beiträge: | 126 | |
| Leser gesamt: | 36941 | |
| davon Heute: | 2 | |
bewertet mit 1 Stern |
||
|
|
||
21.11.16 20:00
#76
chriseb
Löschung
Moderation
Zeitpunkt: 22.11.16 12:05
Aktion: Löschung des Beitrages
Kommentar: Moderation auf Wunsch des Verfassers
Zeitpunkt: 22.11.16 12:05
Aktion: Löschung des Beitrages
Kommentar: Moderation auf Wunsch des Verfassers
21.11.16 22:23
#79
inso
cbyl-kalvista-merger-special-meeting-results:
http://ih.advfn.com/p.php?pid=nmona&article=72966115
21.11.16 22:44
#81
chriseb
Merger hat geklappt
HV hat in allen Punkten mit deutlicher Mehrheit zugestimmt
22.11.16 05:50
#83
Trash
Cashbestand
fast doppelt so hoch wie die jetzige MK ansich, aber die Aktionäre stimmen dennoch einer knapp 20 % künftigen Beteiligung zu . Das kann eigentlich nur heißen : sie sehen von jetzt ab weiterhin mehr kurspotential über 100% hinaus und nehmen da sogar eine 180t Haltefrist in Kauf ...
22.11.16 06:00
#84
Trash
Zusatz
Und das bei einer Pipeline ohne Phase 2-3 Produkte ... sollte man stets im Hinterkopf behalten .
22.11.16 10:44
#85
Akut
Löschung
Moderation
Zeitpunkt: 23.11.16 12:22
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer
Kommentar: Mehrfach gesperrte Nachfolge-ID.
Zeitpunkt: 23.11.16 12:22
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer
Kommentar: Mehrfach gesperrte Nachfolge-ID.
22.11.16 11:04
#86
zagato
Hallo,
wird cbyl heute nicht gehandelt ? Wenn ja, warum nicht ?
Vielen Dank
Zag
Vielen Dank
Zag
22.11.16 11:18
#87
chriseb
Heute
wird der RS kommen, dauert dann diese Woche, bis alle Banken umgestellt haben. Nächste Woche dann nach oben ( gibt nur ca. 900000 frei handelbare Aktien nach RS)
22.11.16 11:27
#88
zagato
Merger wie bei Biodel ?
Wie werden die Aktien gesplitet und warum ? Gibt es danach neue WKN ?
Vielen Dank
zag
Vielen Dank
zag
22.11.16 11:49
#91
zagato
Hallo DA_BUA
vielen Dank aber unter Kalavista kann ich nichts finden.
Trotzdem Danke.
zag
Trotzdem Danke.
zag
22.11.16 12:49
#92
chriseb
Hier
http://www.ariva.de/kalvista_pharmaceuticals,_inc._common_stock-aktie
Vielleicht sollte man sich etwas informieren, bevor man investiert.
Vielleicht sollte man sich etwas informieren, bevor man investiert.
22.11.16 14:20
#98
Gordon Gekko1981.
Kurze Frage
Ich habe 2100 cbyl Aktien im depot! Da wurde noch nichts geändert! Wie wäre der aktuelle Stand meiner Werte?
22.11.16 16:55
#100
tolksvar
hier die neusten news
Get it on Google Play
KalVista (KALV) Reports Closing of Merger with Carbylan Therapeutics
Article
Related Press Releases (1)
Stock Quotes (1)
Comments (0)
FREE Breaking News Alerts from StreetInsider.com!
E-mail Address
StreetInsider.com Top Tickers, 11/22/2016
1. GOLF
2. PANW
3. JACK
4. DLTR
5. GOOGL
6. BL
7. ENTA
8. BAC
9. ALDR
10. FEYE
.
Top News
Most Read
Special Reports
Wall St. at record high, Dow tops 19,000 for first time
Post-Election Themes a Mixed Blessing for Hedge Funds; 13 New Stocks Added to Goldman Sachs Hedge Fund VIP List
Palo Alto Networks (PANW) Reports In-Line Q1 EPS; Guides Q2 Revenue Below Views
Oil prices at highs for November on hopes of OPEC deal
Dr Pepper Snapple Group (DPS) to Acquire Bai Brands for $1.7B
November 22, 2016 7:32 AM EST
Tweet Share E-mail
Get Alerts KALV Hot Sheet
Price: $7.34 -98.49%
Trade KALV Now!
Join SI Premium – FREE
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced the closing of the previously announced merger with Carbylan Therapeutics, Inc. As a result of the completion of this transaction, Carbylan changed its name to KalVista Pharmaceuticals, Inc. The Company will commence trading on November 22, 2016 on the NASDAQ Stock Market under the symbol “KALV”.
KalVista is now funded with more than $38 million to support its portfolio of drug development programs, initially focused on oral plasma kallikrein treatments for hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing a portfolio of drugs for HAE, with the first oral HAE candidate, KVD818, having commenced a Phase I clinical trial in the third quarter of 2016. Additional HAE candidates are planned to begin clinical trials in 2017 and beyond. KalVista’s objective is to advance multiple oral drug candidates through Phase I, first-in-human studies in order to select those with the potential to deliver best-in-class status for further development. KalVista is also developing KVD001, an intravitreally-delivered therapy for DME. This program has completed a Phase I clinical trial in DME patients and is expected to progress to Phase II clinical development in 2017.
In conjunction with the closing, KalVista welcomed Benjamin L. Palleiko as the Chief Financial Officer of KalVista. Mr. Palleiko has over twenty years of experience in the industry, as both a senior life sciences investment banker and Chief Financial Officer of several public and private life sciences companies. He has raised more than $2 billion in capital and completed over 50 transactions in his business career. Mr. Palleiko holds a MBA in Finance and a MA in International Relations from the University of Chicago, and a BA in Quantitative Economics from Tufts University. Prior to graduate school, he served in the U.S. Navy as a Naval Aviator flying carrier-based jet aircraft.
“The transition of KalVista to the public markets is an important milestone in the strategic development of the Company as we advance our pipeline of novel serine protease therapeutics,” said Andrew Crockett, KalVista’s Chief Executive Officer. “With the capital raised in this transaction and an experienced leadership team, KalVista is even better positioned to accelerate our clinical programs to bring new treatment options to patients with hereditary angioedema and diabetic macular edema. We also are particularly pleased that Ben Palleiko has chosen to join us as CFO at this time, as his deep background and skills will help us as we enter the next phase of growing shareholder value as a public company.”
The executive leadership of the new Company is comprised of members of the KalVista management team, with members of the Carbylan team departing the Company. The management team is initially comprised of Mr. Crockett as Chief Executive Officer; Christopher Yea, Ph.D. as Chief Development Officer; and Mr. Palleiko as Chief Financial Officer. The board of directors is comprised of seven members, consisting of five members designated by KalVista: Richard Aldrich, who will serve as Chairman, Joshua Resnick, M.D., Rajeev Shah, Edward W. Unkart and Mr. Crockett; and two members designated by Carbylan, Albert Cha, M.D., Ph.D, and Arnold L. Oronsky, Ph.D. The Company has offices in Cambridge, MA and Porton Down, U.K.
KalVista (KALV) Reports Closing of Merger with Carbylan Therapeutics
Article
Related Press Releases (1)
Stock Quotes (1)
Comments (0)
FREE Breaking News Alerts from StreetInsider.com!
E-mail Address
StreetInsider.com Top Tickers, 11/22/2016
1. GOLF
2. PANW
3. JACK
4. DLTR
5. GOOGL
6. BL
7. ENTA
8. BAC
9. ALDR
10. FEYE
.
Top News
Most Read
Special Reports
Wall St. at record high, Dow tops 19,000 for first time
Post-Election Themes a Mixed Blessing for Hedge Funds; 13 New Stocks Added to Goldman Sachs Hedge Fund VIP List
Palo Alto Networks (PANW) Reports In-Line Q1 EPS; Guides Q2 Revenue Below Views
Oil prices at highs for November on hopes of OPEC deal
Dr Pepper Snapple Group (DPS) to Acquire Bai Brands for $1.7B
November 22, 2016 7:32 AM EST
Tweet Share E-mail
Get Alerts KALV Hot Sheet
Price: $7.34 -98.49%
Trade KALV Now!
Join SI Premium – FREE
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced the closing of the previously announced merger with Carbylan Therapeutics, Inc. As a result of the completion of this transaction, Carbylan changed its name to KalVista Pharmaceuticals, Inc. The Company will commence trading on November 22, 2016 on the NASDAQ Stock Market under the symbol “KALV”.
KalVista is now funded with more than $38 million to support its portfolio of drug development programs, initially focused on oral plasma kallikrein treatments for hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing a portfolio of drugs for HAE, with the first oral HAE candidate, KVD818, having commenced a Phase I clinical trial in the third quarter of 2016. Additional HAE candidates are planned to begin clinical trials in 2017 and beyond. KalVista’s objective is to advance multiple oral drug candidates through Phase I, first-in-human studies in order to select those with the potential to deliver best-in-class status for further development. KalVista is also developing KVD001, an intravitreally-delivered therapy for DME. This program has completed a Phase I clinical trial in DME patients and is expected to progress to Phase II clinical development in 2017.
In conjunction with the closing, KalVista welcomed Benjamin L. Palleiko as the Chief Financial Officer of KalVista. Mr. Palleiko has over twenty years of experience in the industry, as both a senior life sciences investment banker and Chief Financial Officer of several public and private life sciences companies. He has raised more than $2 billion in capital and completed over 50 transactions in his business career. Mr. Palleiko holds a MBA in Finance and a MA in International Relations from the University of Chicago, and a BA in Quantitative Economics from Tufts University. Prior to graduate school, he served in the U.S. Navy as a Naval Aviator flying carrier-based jet aircraft.
“The transition of KalVista to the public markets is an important milestone in the strategic development of the Company as we advance our pipeline of novel serine protease therapeutics,” said Andrew Crockett, KalVista’s Chief Executive Officer. “With the capital raised in this transaction and an experienced leadership team, KalVista is even better positioned to accelerate our clinical programs to bring new treatment options to patients with hereditary angioedema and diabetic macular edema. We also are particularly pleased that Ben Palleiko has chosen to join us as CFO at this time, as his deep background and skills will help us as we enter the next phase of growing shareholder value as a public company.”
The executive leadership of the new Company is comprised of members of the KalVista management team, with members of the Carbylan team departing the Company. The management team is initially comprised of Mr. Crockett as Chief Executive Officer; Christopher Yea, Ph.D. as Chief Development Officer; and Mr. Palleiko as Chief Financial Officer. The board of directors is comprised of seven members, consisting of five members designated by KalVista: Richard Aldrich, who will serve as Chairman, Joshua Resnick, M.D., Rajeev Shah, Edward W. Unkart and Mr. Crockett; and two members designated by Carbylan, Albert Cha, M.D., Ph.D, and Arnold L. Oronsky, Ph.D. The Company has offices in Cambridge, MA and Porton Down, U.K.